



Foot and Mouth Disease Virus and Novel Vaccines Developments

Guest Editor:

Dr. Elizabeth Rieder

Foreign Animal Disease Research
Unit, United States Department
of Agriculture, Agricultural
Research Service, Plum Island
Animal Disease Center,
Greenport, NY 11944, USA

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

Dear Colleagues,

Foot-and-mouth disease (FMD) is a contagious vesicular disease caused by a highly variable RNA virus (FMDV) affecting cloven-hoofed animals with severe social and economic consequences worldwide. Chemically inactivated whole virus vaccines have been used to contain the disease, but are slow acting and do not always permit distinction between infected and vaccinated animals. New rapid vaccines and emergency response measures, such as therapeutics, need to be developed to allow for rapid containment of future FMDV outbreaks in addition to methods that distinguish between infected and vaccinated animals.

This Special Issue will cover FMDV determinant of replication and pathogenesis and how this information has facilitated next-generation FMDV vaccine and biotherapeutic developments. We particularly encourage the submission of manuscripts focused on improved control strategies addressing important gaps of the current inactivated FMDV vaccine including, but not limited to, duration of immunity, crossreactivity, correlates of protection, early protection, antigen load, immunization responses, and safer marker vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)